Myles Minter
Stock Analyst at William Blair
(2.18)
# 2,218
Out of 4,667 analysts
18
Total ratings
57.14%
Success rate
1.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Initiates: Outperform | n/a | $6.09 | - | 1 | Nov 5, 2024 | |
| ARGX argenx SE | Upgrades: Outperform | n/a | $589.55 | - | 2 | Nov 1, 2024 | |
| KRRO Korro Bio | Initiates: Outperform | n/a | $49.73 | - | 1 | Aug 14, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | n/a | $9.79 | - | 1 | Oct 10, 2023 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Outperform | $71 | $16.68 | +325.66% | 1 | Jul 24, 2023 | |
| MRNA Moderna | Initiates: Market Perform | n/a | $38.39 | - | 1 | Jul 24, 2023 | |
| VRTX Vertex Pharmaceuticals | Initiates: Outperform | n/a | $451.65 | - | 1 | May 30, 2023 | |
| PRAX Praxis Precision Medicines | Downgrades: Market Perform | n/a | $73.50 | - | 2 | Mar 6, 2023 | |
| LRMR Larimar Therapeutics | Upgrades: Outperform | n/a | $6.21 | - | 3 | Sep 19, 2022 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Outperform | n/a | $250.21 | - | 1 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $34.67 | - | 2 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.75 | - | 1 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $116 | $126.09 | -8.00% | 1 | Feb 24, 2020 |
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $6.09
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $589.55
Upside: -
Korro Bio
Aug 14, 2024
Initiates: Outperform
Price Target: n/a
Current: $49.73
Upside: -
Neumora Therapeutics
Oct 10, 2023
Initiates: Outperform
Price Target: n/a
Current: $9.79
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $16.68
Upside: +325.66%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $38.39
Upside: -
Vertex Pharmaceuticals
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $451.65
Upside: -
Praxis Precision Medicines
Mar 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $73.50
Upside: -
Larimar Therapeutics
Sep 19, 2022
Upgrades: Outperform
Price Target: n/a
Current: $6.21
Upside: -
Alnylam Pharmaceuticals
Jun 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $250.21
Upside: -
Dec 14, 2021
Upgrades: Outperform
Price Target: n/a
Current: $34.67
Upside: -
Sep 27, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.75
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: $116
Current: $126.09
Upside: -8.00%